Toxoplasma gondii sustains survival by regulating cholesterol biosynthesis and uptake via SREBP2 activation

Yi‐Min Fan, Qingqi Zhang, Pan Ming, Zhaofeng Hou, Lizhi Fu, Xiulong Xu, Si‐Yang HuangJournal of Lipid Research 2024 · DOI

TL;DR

Toxoplasma gondii, an intracellular parasite, hijacks host cells to obtain essential cholesterol for its survival and replication. This study reveals that T. gondii activates the host's SREBP2 pathway, a master regulator of cholesterol synthesis and uptake, to ensure a steady supply of this vital lipid. Targeting SREBP2 or key enzymes in this pathway shows promise for developing new treatments against toxoplasmosis.

What Problem Does This Paper Address?

Toxoplasma gondii is a widespread parasite that can cause severe illness, particularly in immunocompromised individuals. A major challenge in treating toxoplasmosis is that the parasite cannot produce its own cholesterol and must scavenge it from the host. While it's known that T. gondii needs host cholesterol for invasion, replication, and forming persistent cysts, the precise mechanisms by which the parasite manipulates host cholesterol metabolism have remained unclear. This paper aims to unravel how T. gondii ensures its cholesterol supply by investigating its impact on host cholesterol biosynthesis and uptake pathways and identifying the key host regulators involved.

Methods

The researchers employed a multi-pronged approach to investigate the role of SREBP2 in T. gondii infection:

  • Gene Expression Analysis: Quantitative PCR (qPCR) was used to measure the mRNA levels of key host genes involved in cholesterol synthesis (e.g., HMGCR, SQLE, DHCR7) and uptake (LDLR) in infected cells.
  • Protein Expression Analysis: Western blotting was used to assess the protein levels of these cholesterol-related genes and the active form of SREBP2 (N-SREBP2) in infected cells.
  • Cellular Localization: Immunofluorescence microscopy was used to visualize the nuclear translocation of SREBP2 in infected host cells, indicating its activation.
  • Pharmacological Inhibition: The DHCR7 inhibitor AY9944 was used to block cholesterol biosynthesis and assess its effect on parasite replication and host cell viability.
  • Gene Knockdown: SREBP2 was knocked down in host cells using shRNA to determine its necessity for parasite invasion, replication, and cholesterol accumulation.
  • Parasite Assays:
    • Invasion Assay: A green/red fluorescence assay was used to quantify the rate at which T. gondii invaded host cells.
  • Replication Assay: qPCR was used to measure parasite DNA copy numbers, and fluorescence microscopy was used to count tachyzoites within parasitophorous vacuoles (PVs).
  • Cholesterol Detection: Filipin staining, a fluorescent marker for unesterified cholesterol, was used to visualize cholesterol levels within host cells and parasites.
  • Bradyzoite Differentiation and Cyst Formation Assay: The Pru strain of T. gondii was used to assess bradyzoite differentiation and cyst formation under different conditions in WT and SREBP2 knockdown cells.
  • Cell Viability Assays: Annexin V/PI staining and LDH release assays were used to assess the impact of drug treatments on host cell apoptosis and cytotoxicity.

Datasets

Not discussed in the paper. The study primarily uses established cell lines (HeLa, NL20, HFF) and T. gondii strains (RH, RFP-RHm, PRU).

Key Insights and Ideas

  • Parasite's Cholesterol Dependency is Deeper Than Thought: T. gondii doesn't just "take" cholesterol; it actively manipulates host machinery to increase its supply. This highlights a sophisticated parasitic strategy.
  • SREBP2 is the Master Switch: The study pinpoints SREBP2 as the central host protein that T. gondii hijacks. Its activation leads to a cascade of increased cholesterol synthesis and uptake, directly benefiting the parasite.
  • Nuclear Translocation is Key: The observation that T. gondii infection drives SREBP2 from the cytoplasm to the nucleus is a critical piece of evidence for its activation and subsequent transcriptional control of cholesterol-related genes.
  • Targeting SREBP2 Impairs Multiple Parasite Stages: Knocking down SREBP2 not only reduced parasite replication and invasion but also affected cholesterol accumulation within the parasite, suggesting a broad impact on parasite fitness.
  • DHCR7 Inhibition is a Viable Strategy: The drug AY9944, which inhibits DHCR7 (a key enzyme in cholesterol synthesis), effectively reduced T. gondii replication, validating this pathway as a potential therapeutic target.
  • Bradyzoite Development is Also Affected: While SREBP2 knockdown didn't prevent bradyzoite differentiation, it significantly reduced the number and size of cysts, suggesting a role in the chronic phase of infection.

Key Results

  • T. gondii infection significantly upregulated the expression of host cholesterol synthesis genes (HMGCR, SQLE, DHCR7) and the uptake gene (LDLR) in a time- and dose-dependent manner.
  • T. gondii infection induced the nuclear translocation of SREBP2, indicating its activation.
  • Knockdown of SREBP2 in host cells led to a significant decrease in T. gondii replication, invasion, and intracellular cholesterol accumulation.
  • Inhibition of DHCR7 with AY9944 significantly reduced T. gondii replication without affecting host cell viability at the tested concentrations.
  • SREBP2 knockdown cells showed reduced numbers and sizes of T. gondii cysts.

Limitations and Future Work

  • In Vitro Focus: The study was primarily conducted in vitro using cell lines. While informative, future work should validate these findings in animal models to better understand the in vivo implications.
  • Bradyzoite Differentiation Mechanism: While SREBP2 knockdown affected cyst growth and replication, its precise role in the initial differentiation process remains to be fully elucidated.
  • Host Immune Response Interaction: The paper briefly mentions SREBP2's link to immune pathways. Further research could explore how T. gondii's manipulation of SREBP2 interacts with or evades the host immune response.
  • Therapeutic Potential: The study highlights AY9944 and SREBP2 as potential therapeutic targets. Future work should focus on developing safe and effective drugs that can target these pathways for treating toxoplasmosis, particularly chronic infections.
  • Mechanisms of Invasion and Cyst Formation: While the study shows that reduced cholesterol impacts invasion and cyst growth, the specific molecular mechanisms underlying these effects warrant further investigation.

Summary updated

Abstract

Toxoplasma gondii (T. gondii) is an obligate intracellular parasite that cannot biosynthesize cholesterol via the mevalonate pathway, it sources this lipid from its host. We discovered that T. gondii infection upregulated the expression of host cholesterol synthesis-related genes HMG-CoA reductase(HMGCR), squalene epoxidase (SQLE), and dehydrocholesterol reductase-7 (DHCR7), and increased the uptake pathway gene low-density lipoprotein receptor (LDLR). We found a protein, sterol regulatory element binding protein 2 (SREBP2), which is the key protein regulating the host cholesterol synthesis and uptake during T. gondii infection. T. gondii induced a dose-dependent nuclear translocation of SREBP2. Knockdown SREBP2 reduced T. gondii-induced cholesterol biosynthesis and uptake. Consequently, the parasite's ability to acquire cholesterol was significantly diminished, impairing its invasion, replication, and bradyzoites development. Interfering cholesterol metabolism using AY9944 effectively inhibited T. gondii replication. In summary, SREBP2 played an important role in T. gondii infection in vitro, serving as a potential target for regulating T. gondii-induced cholesterol metabolism, offering insights into the prevention and treatment of toxoplasmosis.
BibTeX
@article{fan2024toxoplasma,
  author = {Yi‐Min Fan and Qingqi Zhang and Pan Ming and Zhaofeng Hou and Lizhi Fu and Xiulong Xu and Si‐Yang Huang},
  title = {{Toxoplasma gondii sustains survival by regulating cholesterol biosynthesis and uptake via SREBP2 activation}},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100684},
}
Figure